COMMITTEE | Base Accrual 2010 |
2022 Accrual to date |
Percentage of Base Accrual |
Projected 2022 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
BREAST | 1558 | 59 | 4% | 115 | -1442 | 161 | -1397 |
ERLYTX | 76 | 7 | 9% | 13 | -62 | 30 | -46 |
GI | 476 | 49 | 10% | 96 | -379 | 113 | -363 |
GU | 450 | 189 | 42% | 370 | -79 | 409 | -41 |
GYN | 57 | 0 | 0% | 0 | -57 | 0 | -57 |
LEUK | 150 | 46 | 31% | 90 | -59 | 108 | -42 |
LUNG | 524 | 179 | 34% | 351 | -172 | 338 | -186 |
LYMPH | 172 | 272 | 158% | 533 | 361 | 510 | 338 |
MELAN | 55 | 58 | 105% | 113 | 58 | 128 | 73 |
MMYEL | 147 | 165 | 112% | 323 | 176 | 344 | 197 |
OTHER | 0 | 25 | 49 | 49 | 47 | 47 | |
0 | 2 | 3 | 3 | 3 | 3 | ||
SXQOL | 0 | 0 | 0 | 0 | 5 | 5 | |
Total | 3665 | 1051 | 2056 | -1603 | 2196 | -1469 |
COMMITTEE | Base Accrual 2010 |
2022 Accrual to date |
Percentage of Base Accrual |
Projected 2022 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
3 | 6 | 200% | 11 | 8 | 6 | 3 | |
BREAST | 37 | 1 | 3% | 1 | -35 | 1 | -36 |
CCD | 0 | 91 | 178 | 178 | 184 | 184 | |
GU | 0 | 11 | 21 | 21 | 24 | 24 | |
LEUK | 69 | 0 | 0% | 0 | -69 | 0 | -69 |
LUNG | 43 | 299 | 695% | 586 | 543 | 508 | 465 |
LYMPH | 53 | 0 | 0% | 0 | -53 | 0 | -53 |
MMYEL | 92 | 0 | 0% | 0 | -92 | 0 | -92 |
OTHER | 0 | 45 | 88 | 88 | 120 | 120 | |
PEOLC | 0 | 16 | 31 | 31 | 32 | 32 | |
PREV | 0 | 471 | 924 | 924 | 1011 | 1011 | |
SURV | 0 | 13 | 25 | 25 | 25 | 25 | |
SXQOL | 888 | 303 | 34% | 594 | -293 | 697 | -191 |
Total | 1185 | 1256 | 2459 | 1276 | 2608 | 1423 |
COMMITTEE | Base Accrual 2010 |
2022 Accrual to date |
Percentage of Base Accrual |
Projected 2022 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
3 | 6 | 200% | 11 | 8 | 6 | 3 | |
BREAST | 1595 | 60 | 4% | 117 | -1477 | 162 | -1433 |
CCD | 0 | 91 | 178 | 178 | 184 | 184 | |
ERLYTX | 76 | 7 | 9% | 13 | -62 | 30 | -46 |
GI | 476 | 49 | 10% | 96 | -379 | 113 | -363 |
GU | 450 | 200 | 44% | 392 | -57 | 433 | -17 |
GYN | 57 | 0 | 0% | 0 | -57 | 0 | -57 |
LEUK | 219 | 46 | 21% | 90 | -128 | 108 | -111 |
LUNG | 567 | 478 | 84% | 938 | 371 | 846 | 279 |
LYMPH | 225 | 272 | 121% | 533 | 308 | 510 | 285 |
MELAN | 55 | 58 | 105% | 113 | 58 | 128 | 73 |
MMYEL | 239 | 165 | 69% | 323 | 84 | 344 | 105 |
OTHER | 0 | 70 | 137 | 137 | 167 | 167 | |
0 | 2 | 3 | 3 | 3 | 3 | ||
PEOLC | 0 | 16 | 31 | 31 | 32 | 32 | |
PREV | 0 | 471 | 924 | 924 | 1011 | 1011 | |
SURV | 0 | 13 | 25 | 25 | 25 | 25 | |
SXQOL | 888 | 303 | 34% | 594 | -293 | 702 | -186 |
Total | 4850 | 2307 | 4518 | -326 | 4804 | -46 |
COMMITTEE | Base Accrual 2010 |
2022 Accrual to date |
Percentage of Base Accrual |
Projected 2022 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
BREAST | 1012 | 51 | 5% | 100 | -911 | 127 | -885 |
ERLYTX | 76 | 5 | 7% | 9 | -66 | 20 | -56 |
GI | 418 | 42 | 10% | 82 | -335 | 103 | -315 |
GU | 375 | 129 | 34% | 253 | -121 | 278 | -97 |
GYN | 57 | 0 | 0% | 0 | -57 | 0 | -57 |
LEUK | 122 | 38 | 31% | 74 | -47 | 94 | -28 |
LUNG | 441 | 121 | 27% | 237 | -203 | 240 | -201 |
LYMPH | 129 | 122 | 95% | 239 | 110 | 237 | 108 |
MELAN | 55 | 38 | 69% | 74 | 19 | 88 | 33 |
MMYEL | 85 | 97 | 114% | 190 | 105 | 209 | 124 |
OTHER | 0 | 25 | 49 | 49 | 47 | 47 | |
0 | 2 | 3 | 3 | 3 | 3 | ||
SXQOL | 0 | 0 | 0 | 0 | 5 | 5 | |
Total | 2770 | 670 | 1310 | -1454 | 1451 | -1319 |
COMMITTEE | Base Accrual 2010 |
2022 Accrual to date |
Percentage of Base Accrual |
Projected 2022 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
3 | 6 | 200% | 11 | 8 | 6 | 3 | |
BREAST | 10 | 1 | 10% | 1 | -8 | 1 | -9 |
CCD | 0 | 84 | 164 | 164 | 175 | 175 | |
GU | 0 | 11 | 21 | 21 | 24 | 24 | |
LEUK | 69 | 0 | 0% | 0 | -69 | 0 | -69 |
LUNG | 30 | 160 | 533% | 313 | 283 | 281 | 251 |
LYMPH | 53 | 0 | 0% | 0 | -53 | 0 | -53 |
MMYEL | 92 | 0 | 0% | 0 | -92 | 0 | -92 |
OTHER | 0 | 45 | 88 | 88 | 120 | 120 | |
PEOLC | 0 | 7 | 13 | 13 | 19 | 19 | |
PREV | 0 | 339 | 665 | 665 | 764 | 764 | |
SURV | 0 | 10 | 19 | 19 | 22 | 22 | |
SXQOL | 750 | 237 | 32% | 465 | -284 | 543 | -207 |
Total | 1007 | 900 | 1760 | 755 | 1955 | 948 |
COMMITTEE | Base Accrual 2010 |
2022 Accrual to date |
Percentage of Base Accrual |
Projected 2022 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
3 | 6 | 200% | 11 | 8 | 6 | 3 | |
BREAST | 1022 | 52 | 5% | 102 | -919 | 128 | -894 |
CCD | 0 | 84 | 164 | 164 | 175 | 175 | |
ERLYTX | 76 | 5 | 7% | 9 | -66 | 20 | -56 |
GI | 418 | 42 | 10% | 82 | -335 | 103 | -315 |
GU | 375 | 140 | 37% | 274 | -100 | 302 | -73 |
GYN | 57 | 0 | 0% | 0 | -57 | 0 | -57 |
LEUK | 191 | 38 | 20% | 74 | -116 | 94 | -97 |
LUNG | 471 | 281 | 60% | 551 | 80 | 521 | 50 |
LYMPH | 182 | 122 | 67% | 239 | 57 | 237 | 55 |
MELAN | 55 | 38 | 69% | 74 | 19 | 88 | 33 |
MMYEL | 177 | 97 | 55% | 190 | 13 | 209 | 32 |
OTHER | 0 | 70 | 137 | 137 | 167 | 167 | |
0 | 2 | 3 | 3 | 3 | 3 | ||
PEOLC | 0 | 7 | 13 | 13 | 19 | 19 | |
PREV | 0 | 339 | 665 | 665 | 764 | 764 | |
SURV | 0 | 10 | 19 | 19 | 22 | 22 | |
SXQOL | 750 | 237 | 32% | 465 | -284 | 548 | -202 |
Total | 3777 | 1570 | 3072 | -699 | 3406 | -371 |
COMMITTEE | Base Accrual 2010 |
2022 Accrual to date |
Percentage of Base Accrual |
Projected 2022 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
BREAST | 65 | 15 | 23% | 29 | -35 | 75 | 10 |
CCD | 0 | 91 | 178 | 178 | 184 | 184 | |
ERLYTX | 0 | 0 | 0 | 0 | 1 | 1 | |
GI | 81 | 11 | 14% | 21 | -59 | 38 | -43 |
GU | 215 | 153 | 71% | 300 | 85 | 351 | 136 |
LEUK | 0 | 14 | 27 | 27 | 22 | 22 | |
LUNG | 53 | 79 | 149% | 155 | 102 | 152 | 99 |
LYMPH | 7 | 241 | 3443% | 472 | 465 | 432 | 425 |
MELAN | 0 | 0 | 0 | 0 | 0 | 0 | |
MMYEL | 0 | 7 | 13 | 13 | 11 | 11 | |
OTHER | 0 | 7 | 13 | 13 | 19 | 19 | |
0 | 0 | 0 | 0 | 1 | 1 | ||
PEOLC | 0 | 16 | 31 | 31 | 32 | 32 | |
PREV | 0 | 232 | 455 | 455 | 486 | 486 | |
SURV | 0 | 13 | 25 | 25 | 25 | 25 | |
SXQOL | 880 | 303 | 34% | 594 | -285 | 702 | -178 |
Total | 1301 | 1182 | 2313 | 1015 | 2531 | 1230 |
Comm. | Phase | Study | Stat Center |
Open Date |
Months Open |
Total Regs |
Accrual Goal |
Monthly Accrual Rate |
Date of Expected Closure or Temporary Closure |
---|---|---|---|---|---|---|---|---|---|
S2015 | SWOG | 6 | |||||||
BIOL | SLA01 LA Gastric Ca, Immune Checkpoint Expression | SWOG | 02APR2019:00:00:00 | 39 | 0 | 400 | 0.0 | > 15 Yrs | |
BREAST | I-II | EA1183 Brst, Met, FDG PET Assess Response, FEATURE | ECOG-ACRIN | 02APR2020:00:00:00 | 10 | 0.2 | |||
II | EA1181 BRST, HER2-pCR, Preop THP and Postop HP | ECOG-ACRIN | 11FEB2020:00:00:00 | 82 | 6.2 | ||||
NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv | NRG | 13APR2017:00:00:00 | 7 | Jul-2019 Temp Close | |||||
S1706 Breast, Inflammatory, RT +/- Olaparib | SWOG | 12SEP2018:00:00:00 | 45 | 104 | 300 | 1.2 | Jun-2036 | ||
S2007 Breast, Brain Mets, Sacituzumab Govitecan | SWOG | 15DEC2020:00:00:00 | 18 | 11 | 44 | 1.2 | Nov-2024 | ||
II-III | NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA | NRG | 24DEC2014:00:00:00 | 1 | Sep-2019 Temp Close | ||||
III | A011202 Breast, Nodal XRT +/- ALND | ALLIANCE | 07FEB2014:00:00:00 | 129 | 0.0 | ||||
A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib | ALLIANCE | 06JAN2021:00:00:00 | 10 | 0.5 | |||||
MA39 BREAST, Node-Pos, Reg RT vs No Reg RT | CCTG | 30MAY2018:00:00:00 | 10 | 0.3 | |||||
NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo | NRG | 22JAN2015:00:00:00 | 89 | 0.0 | |||||
NRGBR004 BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo | NRG | 12MAR2019:00:00:00 | 9 | 0.3 | |||||
NRGBR007 Breast, Stg I, De-Escalation of Breast RT | NRG | 07JUN2021:00:00:00 | 1 | 0.2 | |||||
CCD | II | EAQ171CD Smoke Free Support Study 2.0 | ECOG-ACRIN | 11APR2019:00:00:00 | 3 | 0.3 | |||
III | A191901 Brst, Text/Motivational Intervention ET Adher | ALLIANCE | 10DEC2020:00:00:00 | 36 | 2.7 | ||||
S1703 Met Breast, STM-monitoring v Usual Care | SWOG | 16JUL2018:00:00:00 | 47 | 228 | 1320 | 4.7 | > 15 Yrs | ||
S1912CD CREDIT, Fin Counseling to reduce Fin Hardship | SWOG | 26JUL2021:00:00:00 | 11 | 30 | 536 | 4.0 | Jan-2033 | ||
OTHER | A231601C CCD, OPTI-Surg in older cancer patients | ALLIANCE | 01APR2019:00:00:00 | 1 | 0.0 | ||||
A231602C Blood Cancer, Assess Financial Difficulty | ALLIANCE | 15MAR2019:00:00:00 | 4 | Feb-2021 Temp Close | |||||
A231701C Brst, Srg Decision Engagement | ALLIANCE | 01MAR2019:00:00:00 | 1 | 0.0 | |||||
A231901C Breast, Shared Decision Engagement System | ALLIANCE | 15JAN2021:00:00:00 | 1 | 0.2 | |||||
ACCL16N1 Guideline Consistent Treatment AYA ALL | COG | 18DEC2017:00:00:00 | 54 | Mar-2020 Temp Close | |||||
NHLBIMDS LEUK, National MDS Study | ECOG-ACRIN | 05APR2016:00:00:00 | 166 | 3.2 | |||||
NRGCC007 CCD, Increased Dose of SCP in Pros Survivors | NRG | 27MAR2019:00:00:00 | 23 | 0.2 | |||||
ERLYTX | II | S1609 Rare Tumor, Comb Nivo/Ipi | SWOG | 13JAN2017:00:00:00 | 65 | 793 | 818 | 0.7 | Aug-2025 |
II-III | S2012 Small Cell NEC, Stg IV, Combo Chemo +/- Atezo | SWOG | 02DEC2021:00:00:00 | 7 | 1 | 189 | 0.2 | > 15 Yrs | |
III | AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | COG | 08MAY2017:00:00:00 | 1 | 0.0 | ||||
OTHER | EAY131 MATCH | ECOG-ACRIN | 12AUG2015:00:00:00 | 183 | 0.0 | ||||
GI | II | EA2182 Anal, Erly, DECREASE | ECOG-ACRIN | 12NOV2019:00:00:00 | 2 | 0.3 | |||
EA2186 PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI | ECOG-ACRIN | 18JUN2020:00:00:00 | 16 | 0.3 | |||||
EA2187 ICC, Carboplatin+Paclitaxel +/- Pevonedistat | ECOG-ACRIN | 31JAN2020:00:00:00 | 7 | 0.0 | |||||
S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | SWOG | 16DEC2019:00:00:00 | 30 | 21 | 94 | 0.3 | > 15 Yrs | ||
S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | SWOG | 04DEC2020:00:00:00 | 19 | 15 | 88 | 1.7 | Feb-2026 | ||
S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs | SWOG | 14OCT2021:11:13:50 | 8 | 4 | 154 | 0.7 | > 15 Yrs | ||
S2107 Colorectal, BRAF mut, Enc + CET +/-Nivo | SWOG | 06JUN2022:10:01:28 | 0 | 0 | 84 | ||||
II-III | EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab | ECOG-ACRIN | 17JAN2019:00:00:00 | 2 | 0.2 | ||||
EA2197 Gal, Rando Perioperative TX | ECOG-ACRIN | 22DEC2020:00:00:00 | 2 | 0.2 | |||||
NRGGI005 COLON,Stg IIA, ctDNA in Adjuvant Chemotherapy | NRG | 16DEC2019:00:00:00 | 30 | 20 | 1.2 | ||||
III | A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC | ALLIANCE | 12SEP2017:00:00:00 | 59 | 0.5 | ||||
A021602 PANC, Adv PNET Blinded Cabozantinib v Placebo | ALLIANCE | 18JUL2018:00:00:00 | 17 | 0.2 | |||||
A021703 COLON, Adv/Met, Chemo + Std v High dose V-D3 | ALLIANCE | 30SEP2019:00:00:00 | 24 | 0.8 | |||||
A021806 Pancreas, Perioperative vs Adjuvant Chemo | ALLIANCE | 01JUL2020:00:00:00 | 16 | 0.5 | |||||
EA2176 Anal, Met, Immune Check Pt Inhibition + Chemo | ECOG-ACRIN | 15OCT2020:00:00:00 | 12 | 1.2 | |||||
NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy | NRG | 07NOV2017:00:00:00 | 55 | 15 | 0.0 | ||||
GU | II | A031701 Bladder, ddGC for MIBC with DDR Tumor Alt | ALLIANCE | 01AUG2018:00:00:00 | 10 | 0.3 | |||
A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) | ALLIANCE | 12APR2019:00:00:00 | 23 | 0.5 | |||||
A031801 GU, mRCC, Cabozantinib +/- Radium-223 | ALLIANCE | 13DEC2019:00:00:00 | 6 | 0.3 | |||||
A031803 Blad, NMIBC, Gemcitabine + MK-3475 | ALLIANCE | 06JAN2020:00:00:00 | 24 | 1.2 | |||||
EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi | ECOG-ACRIN | 09JUL2018:00:00:00 | 70 | 1.7 | |||||
S2011 Blad, MIBC,Gem+Carbo+Avelumab+Srg vs Srg Only | SWOG | 06OCT2021:11:28:41 | 8 | 0 | 196 | 0.0 | > 15 Yrs | ||
II-III | EA8192 Blad, High Grade UTUC, Durv + Chemo | ECOG-ACRIN | 06MAY2021:00:00:00 | 1 | 0.2 | ||||
NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel | NRG | 30DEC2016:00:00:00 | 4 | 0.0 | |||||
III | A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) | ALLIANCE | 01JUL2015:00:00:00 | 12 | 0.2 | ||||
A031704 RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo | ALLIANCE | 09MAY2019:00:00:00 | 90 | 1.8 | |||||
A031902 Pros, Adv, Enzalutamide + Rucaparib | ALLIANCE | 19FEB2021:00:00:00 | 4 | 0.2 | |||||
EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT | ECOG-ACRIN | 08SEP2017:00:00:00 | 8 | 0.0 | |||||
EA8183 Pros, Dbl Blind Andro Dep + Daro vs Placebo | ECOG-ACRIN | 09DEC2020:00:00:00 | 3 | 0.0 | |||||
EA8191 Pros, Local vs Systemic Thrpy | ECOG-ACRIN | 08OCT2020:00:00:00 | 1 | 0.0 | |||||
NRGGU005 PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT | NRG | 16NOV2017:00:00:00 | 9 | 0.0 | |||||
NRGGU009 Pros, PREDICT-RT | NRG | 15DEC2020:00:00:00 | 3 | 0.5 | |||||
NRGGU010 Pros, Parallel De-Intens & Intens Trials | NRG | 03NOV2021:00:00:00 | 3 | 0.5 | |||||
S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum | SWOG | 17SEP2018:00:00:00 | 45 | 565 | 1273 | 11.3 | Sep-2027 | ||
S1806 Blad, MIBC, ChemoRT +/- Atezolizumab | SWOG | 19APR2019:00:00:00 | 38 | 294 | 475 | 9.7 | Jan-2024 | ||
S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only | SWOG | 16NOV2020:00:00:00 | 19 | 33 | 332 | 2.7 | Nov-2031 | ||
S1937 Blad, Mets, Eribulin +/- Gem vs SOC | SWOG | 16FEB2021:00:00:00 | 16 | 10 | 465 | 1.0 | > 15 Yrs | ||
LEUK | I-II | S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 | SWOG | 17AUG2020:00:00:00 | 22 | 10 | 64 | 0.3 | Dec-2035 |
II | A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat | ALLIANCE | 16NOV2018:00:00:00 | 4 | 0.0 | ||||
EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs | ECOG-ACRIN | 03OCT2018:00:00:00 | 2 | 0.0 | |||||
S1712 CML, Chronic Phase, TKI +/- Ruxolitinib | SWOG | 20JUL2018:00:00:00 | 47 | 76 | 84 | 1.8 | Nov-2022 | ||
II-III | A041701 AML, Age 60+, Conv Chemo +/- Uproleselan | ALLIANCE | 16JAN2019:00:00:00 | 38 | 0.0 | ||||
III | A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo | ALLIANCE | 01JUN2017:00:00:00 | 44 | 1.0 | ||||
A041702 CLL, Stg I-IV, IO with IM versus IVO | ALLIANCE | 04JAN2019:00:00:00 | 64 | 1.3 | |||||
EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab | ECOG-ACRIN | 14OCT2020:00:00:00 | 16 | 0.7 | |||||
S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O | SWOG | 14DEC2020:00:00:00 | 18 | 27 | 247 | 2.2 | Dec-2030 | ||
LUNG | II | EA5191 NSCLC, Cabozantinib +/- Nivolumab vs Chemo | ECOG-ACRIN | 22MAY2020:00:00:00 | 5 | 0.5 | |||
S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac | SWOG | 09AUG2018:00:00:00 | 46 | 18 | 66 | 0.3 | Jun-2034 | ||
S1900E KRAS G12C: Sotorasib (AMG 510) | SWOG | 02APR2021:00:00:00 | 15 | 66 | 116 | 3.0 | Nov-2023 | ||
S1929 ESCLC, SLFN11+, Atezolizumab ± Talazoparib | SWOG | 15JUN2020:10:13:46 | 24 | 83 | 94 | 4.7 | Sep-2022 | ||
S1933 NSCLC, Stg II-III, RT + Atezo | SWOG | 15JUN2020:10:15:53 | 24 | 23 | 47 | 0.8 | Nov-2024 | ||
S1934 Superior Sulcus NSCLC, Trimodality +/- Atezo | SWOG | 09SEP2021:11:49:38 | 9 | 0 | 74 | 0.0 | > 15 Yrs | ||
II-III | NRGCC003 SCLC, PCI or HA-PCI | NRG | 07DEC2015:00:00:00 | 5 | 0.0 | ||||
NRGLU002 LUNG, Limited Met NSCLC, MST vs LCT + MST | NRG | 07APR2017:00:00:00 | 2 | 0.0 | |||||
NRGLU005 LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo | NRG | 28MAY2019:00:00:00 | 14 | 0.8 | |||||
S1800D Non-Match: N-803 + Pembro vs SoC | SWOG | 15FEB2022:00:00:00 | 4 | 25 | 478 | 5.3 | Jul-2029 | ||
III | A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO | ALLIANCE | 03JUN2020:00:00:00 | 36 | 0.8 | ||||
E4512 ALCHEMIST2, ALK mut, Crizotinib | ECOG-ACRIN | 18AUG2014:00:00:00 | 17 | 0.0 | |||||
EA5163 NSCLC, Immunotherapy +/- 2nd line therapy | ECOG-ACRIN | 28FEB2019:00:00:00 | 52 | 1.2 | |||||
EA5181 NSCLC, Unresect Stg 3, Chemo/RT+/-MED4736 | ECOG-ACRIN | 09APR2020:00:00:00 | 40 | 1.7 | |||||
EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 | ECOG-ACRIN | 22OCT2020:00:00:00 | 3 | 0.2 | |||||
R1308 Lung, Stg II/III, Photon vs Proton Chemo RT | NRG | 03FEB2014:00:00:00 | 1 | 0.0 | |||||
S1827 SCLC, MRI Surveillance +/- PCI | SWOG | 10JAN2020:00:00:00 | 29 | 102 | 668 | 5.3 | May-2031 | ||
S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo | SWOG | 25MAR2020:00:00:00 | 27 | 108 | 480 | 5.8 | Oct-2027 | ||
OTHER | A151216 ALCHEMIST0 - screening | ALLIANCE | 06FEB2014:00:00:00 | 916 | 1.2 | ||||
LUNGMAP NSCLC, Adv, Master | SWOG | 28JAN2019:00:00:00 | 41 | 2567 | 48.3 | ||||
LYMPH | I-II | E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin | ECOG-ACRIN | 24JAN2014:00:00:00 | 20 | 0.0 | |||
II | EA4181 MCL, Randomization BR/CR v BR/CR-A v BR-A | ECOG-ACRIN | 03OCT2019:00:00:00 | 64 | 2.2 | ||||
S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | SWOG | 10AUG2017:00:00:00 | 72 | 103 | Temp Close | ||||
II-III | A051701 LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax | ALLIANCE | 07AUG2019:00:00:00 | 34 | Sep-2020 Temp Close | ||||
S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | SWOG | 19MAR2021:00:00:00 | 15 | 35 | 422 | 2.7 | Aug-2034 | ||
III | A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo | ALLIANCE | 06JUL2016:00:00:00 | 12 | 0.0 | ||||
ANHL1931 PMBCL, Chemo-Immunotherapy +/- Nivo | COG | 07JUN2021:00:00:00 | 1 | 0.2 | |||||
EA4151 Lymph, AHCT +/-Ritux, MRD Neg | ECOG-ACRIN | 29AUG2017:00:00:00 | 103 | 2.8 | |||||
S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD | SWOG | 19JUL2019:00:00:00 | 35 | 894 | 987 | 36.8 | Sep-2022 | ||
MELAN | II | EA6192 Melan, Adv, Erly Discont of Antibdy Thrpy | ECOG-ACRIN | 27AUG2020:00:00:00 | 3 | 0.2 | |||
S2000 MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo | SWOG | 23SEP2020:00:00:00 | 21 | 12 | 112 | 0.3 | > 15 Yrs | ||
II-III | EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim | ECOG-ACRIN | 01MAR2016:00:00:00 | 46 | 0.7 | ||||
III | EA6174 Merkel, Adjuvant Pembrolizumab vs Observation | ECOG-ACRIN | 23JUL2018:00:00:00 | 42 | 1.0 | ||||
MMYEL | II | EAA173 MYEL, SMM, Rd +/- Daratumumab | ECOG-ACRIN | 30APR2019:00:00:00 | 19 | 0.5 | |||
S2005 WM, Prev. Untreated, I/R +/- Venetoclax | SWOG | 24JUN2021:00:00:00 | 12 | 1 | 62 | 0.2 | > 15 Yrs | ||
III | EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | ECOG-ACRIN | 27OCT2020:00:00:00 | 7 | 0.7 | ||||
S1803 MM, Maintenance, Len vs Len/Dara | SWOG | 27JUN2019:00:00:00 | 36 | 801 | 1100 | 26.2 | Jun-2023 | ||
OTHER | II | A071701 BRAIN, Met, Geno-guided trial | ALLIANCE | 15AUG2019:00:00:00 | 1 | 0.0 | |||
A091802 cSCC, Advanced Avelumab +/- Cetuximab | ALLIANCE | 17MAY2019:00:00:00 | 5 | 0.0 | |||||
A091902 Sarcoma, Paclit +/- Nivo and Nivo + Caboz | ALLIANCE | 04SEP2020:00:00:00 | 18 | 0.7 | |||||
EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp | ECOG-ACRIN | 29MAR2016:00:00:00 | 20 | 0.0 | |||||
EA3163 Nasal, T3 vs T4a, Surgery+RT +/- NeoAdj CT | ECOG-ACRIN | 28MAR2018:00:00:00 | 1 | 0.0 | |||||
EA3191 HN, High Risk HNSCC, Adj +/- Pembro | ECOG-ACRIN | 08JAN2021:00:00:00 | 2 | 0.3 | |||||
EAF151 Brain, GBM, Bev, Blood Volume | ECOG-ACRIN | 14APR2017:00:00:00 | 2 | 0.0 | |||||
NRGBN001 HN, novel vs. std chemoradiation + chemo | NRG | 28AUG2015:00:00:00 | 1 | 0.0 | |||||
NRGGY023 Ovar, Rando Durv Triplet TX vs Chemo | NRG | 28APR2021:00:00:00 | 2 | 0.2 | |||||
II-III | EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo | ECOG-ACRIN | 20JUN2019:00:00:00 | 38 | 2.0 | ||||
NRGBN007 Brain, New Dx, Ipi + Nivo vs Temozomide | NRG | 06AUG2020:00:00:00 | 5 | 0.2 | |||||
NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care | NRG | 06FEB2016:00:00:00 | 4 | 0.0 | |||||
NRGHN001 Nasopharyngeal , Indiviual Tx EBV | NRG | 21APR2014:00:00:00 | 7 | 0.0 | |||||
NRGHN004 HN, Adv, RT+Durvalumab vs RT+Cetuximab | NRG | 12DEC2017:00:00:00 | 6 | 0.0 | |||||
NRGHN005 HN, early stg P16-pos, randomize de-intensifi | NRG | 10JUL2019:00:00:00 | 6 | 0.0 | |||||
NRGHN006 HN, Erly Stg, Biopsy vs Dissection | NRG | 08JUL2020:00:00:00 | 1 | 0.0 | |||||
NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN | NRG | 27OCT2021:00:00:00 | 2 | 0.3 | |||||
R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux | NRG | 18MAR2013:00:00:00 | 5 | 0.0 | |||||
III | A071801 Brain, Mets, Post-Srg Single SRS vs Fract SRS | ALLIANCE | 11OCT2019:00:00:00 | 1 | 0.0 | ||||
AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo | COG | 30JUL2018:00:00:00 | 4 | Jan-2021 Temp Close | |||||
ARST1431 Sarcoma, IR RMS, Randomized VAC/VI +/- TORI | COG | 23MAY2016:00:00:00 | 1 | 0.0 | |||||
G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT | NRG | 12APR2010:00:00:00 | 1 | 0.0 | |||||
N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC | ALLIANCE | 22SEP2009:00:00:00 | 13 | 0.2 | |||||
NRGBN003 Mening, Grd II, Observation vs Irradiation | NRG | 14JUN2017:00:00:00 | 3 | 0.0 | |||||
NRGGY018 Endo, Stg III-IVB/Recur, Pac/Carbo +/- Pembro | NRG | 16JUL2019:00:00:00 | 4 | 0.2 | |||||
NRGGY020 Endo, Erly Stg, Rando RT +/- Pembro | NRG | 07FEB2020:00:00:00 | 1 | 0.0 | |||||
R0724 Cervical, Chem+RT +/- Adj. Chemo | NRG | 15JAN2014:00:00:00 | 1 | 0.0 | |||||
OTHER | A151804 irAEs, National Biorepository to Adv Studies | ALLIANCE | 31JAN2020:00:00:00 | 16 | 0.0 | ||||
NCICOVID NCI COVID-19 in Cancer Patients Study | NCI | 21MAY2020:00:00:00 | 329 | 7.2 | |||||
PREV | II | EA2185 Panc, Impact of Panc Cyst Surveillance | ECOG-ACRIN | 16JAN2020:00:00:00 | 8 | 0.5 | |||
III | A211102 Breast, Atypia via RPFNA, Metformin v Placebo | ALLIANCE | 01FEB2015:00:00:00 | 3 | 0.0 | ||||
EA1151 Prev, Tomosynthesis Mammographic Screening | ECOG-ACRIN | 06JUL2017:00:00:00 | 2133 | 39.5 | |||||
S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac | SWOG | 01MAR2013:00:00:00 | 112 | 339 | 491 | 2.2 | May-2028 | ||
OTHER | NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO | NRG | 23JUN2020:00:00:00 | 2 | 0.2 | ||||
S1823 GCT, Obs. Cohort, miRNA371 | SWOG | 01JUN2020:13:00:37 | 25 | 528 | 956 | 22.8 | Jan-2024 | ||
PILOT | S1904 Breast, Decision making for chemoprevention | SWOG | 01SEP2020:00:00:00 | 22 | 183 | 415 | 12.7 | Jan-2024 | |
SURV | III | S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol | SWOG | 15SEP2017:00:00:00 | 57 | 273 | 817 | 2.2 | > 15 Yrs |
SXQOL | II | EAZ171 Breast, Stg I-III, TIPN Docetaxel/Paclitaxel | ECOG-ACRIN | 27JUN2019:00:00:00 | 3 | 0.0 | |||
II-III | A221805 Colorectal, Duloxetine for Oxaliplatin CIPN | ALLIANCE | 01MAY2020:00:00:00 | 5 | 0.2 | ||||
III | A221702 BREAST, SLN/ALND +/- ARM | ALLIANCE | 31MAY2019:00:00:00 | 17 | 0.3 | ||||
A222004 Mult, Olanza vs Megestrol for Anorexia | ALLIANCE | 15OCT2021:00:00:00 | 2 | 0.3 | |||||
S1600 Bladder,Radical Cystectomy Outcomes Nutrition | SWOG | 21FEB2019:00:00:00 | 40 | 140 | 200 | 3.0 | Feb-2024 | ||
S1614 HBV in Ca Pts, anti-HBV therapy vs SOC | SWOG | 21FEB2019:00:00:00 | 40 | 4 | 444 | 0.2 | > 15 Yrs | ||
OTHER | S2013 I-CHECKIT: ICI toxicity risk prediction study | SWOG | 16AUG2021:00:00:00 | 10 | 309 | 2062 | 41.7 | Jan-2026 | |
PILOT | EAQ202 Improving AYA PROs in EA Trials | ECOG-ACRIN | 28OCT2021:00:00:00 | 32 | 4.3 | ||||
Accrual goals assume studies are not terminated early as a result of interim analysis. Studies may have accrual objectives specific to subsets of patients and are not reflected in this report. Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months. Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months. |
Phase | Comm. | Int grp |
Stat Center |
Study | NCIPROTO | CA Cntrl Study |
Temp Close |
---|---|---|---|---|---|---|---|
BIOL | N | SLA01 LA Gastric Ca, Immune Checkpoint Expression | N | ||||
OTHER | CCD | Y | COG | ACCL16N1 Guideline Consistent Treatment AYA ALL | ACCL16N1CD | Y | Y |
Y | ECOG-ACRIN | NHLBIMDS LEUK, National MDS Study | NHLBI-MDS | Y | |||
Y | ALLIANCE | A231602C Blood Cancer, Assess Financial Difficulty | A231602CD | Y | Y | ||
Y | NRG | NRGCC007 CCD, Increased Dose of SCP in Pros Survivors | NRG-CC007CD | Y | |||
Y | ALLIANCE | A231701C Brst, Srg Decision Engagement | A231701CD | Y | |||
Y | ALLIANCE | A231601C CCD, OPTI-Surg in older cancer patients | A231601CD | Y | |||
Y | ALLIANCE | A231901C Breast, Shared Decision Engagement System | A231901CD | Y | |||
ERLYTX | Y | ECOG-ACRIN | EAY131 MATCH | EAY131 | N | ||
LUNG | Y | SWOG | LUNGMAP NSCLC, Adv, Master | LUNGMAP | N | ||
Y | ALLIANCE | A151216 ALCHEMIST0 - screening | A151216 | N | |||
OTHER | Y | ALLIANCE | A151804 irAEs, National Biorepository to Adv Studies | A151804 | N | ||
Y | NCI | NCICOVID NCI COVID-19 in Cancer Patients Study | NCICOVID | N | |||
PREV | Y | SWOG | S1823 GCT, Obs. Cohort, miRNA371 | S1823 | Y | ||
Y | NRG | NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO | NRG-CC008 | Y | |||
SXQOL | Y | SWOG | S2013 I-CHECKIT: ICI toxicity risk prediction study | S2013 | Y | ||
I-II | BREAST | Y | ECOG-ACRIN | EA1183 Brst, Met, FDG PET Assess Response, FEATURE | EA1183 | N | |
LEUK | Y | SWOG | S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 | S1905 | N | ||
LYMPH | Y | ECOG-ACRIN | E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin | E4412 | N | ||
II | BREAST | Y | SWOG | S1706 Breast, Inflammatory, RT +/- Olaparib | S1706 | Y | |
Y | SWOG | S2007 Breast, Brain Mets, Sacituzumab Govitecan | S2007 | N | |||
Y | NRG | NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv | NRG-BR005 | N | Y | ||
Y | ECOG-ACRIN | EA1181 BRST, HER2-pCR, Preop THP and Postop HP | EA1181 | N | |||
CCD | Y | ECOG-ACRIN | EAQ171CD Smoke Free Support Study 2.0 | EAQ171CD | Y | ||
ERLYTX | Y | SWOG | S1609 Rare Tumor, Comb Nivo/Ipi | S1609 | N | ||
GI | Y | SWOG | S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | S2001 | N | ||
Y | SWOG | S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | S1922 | N | |||
Y | SWOG | S2107 Colorectal, BRAF mut, Enc + CET +/-Nivo | S2107 | N | |||
Y | SWOG | S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs | S2104 | N | |||
Y | ECOG-ACRIN | EA2186 PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI | EA2186 | Y | |||
Y | ECOG-ACRIN | EA2182 Anal, Erly, DECREASE | EA2182 | Y | |||
Y | ECOG-ACRIN | EA2187 ICC, Carboplatin+Paclitaxel +/- Pevonedistat | EA2187 | N | |||
GU | Y | SWOG | S2011 Blad, MIBC,Gem+Carbo+Avelumab+Srg vs Srg Only | S2011 | N | ||
Y | ECOG-ACRIN | EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi | EA8171 | N | |||
Y | ALLIANCE | A031701 Bladder, ddGC for MIBC with DDR Tumor Alt | A031701 | N | |||
Y | ALLIANCE | A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) | A031702 | N | |||
Y | ALLIANCE | A031803 Blad, NMIBC, Gemcitabine + MK-3475 | A031803 | N | |||
Y | ALLIANCE | A031801 GU, mRCC, Cabozantinib +/- Radium-223 | A031801 | Y | |||
LEUK | Y | SWOG | S1712 CML, Chronic Phase, TKI +/- Ruxolitinib | S1712 | N | ||
Y | ECOG-ACRIN | EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs | EA9171 | N | |||
Y | ALLIANCE | A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat | A041703 | N | |||
LUNG | Y | SWOG | S1929 ESCLC, SLFN11+, Atezolizumab ± Talazoparib | S1929 | N | ||
Y | SWOG | S1933 NSCLC, Stg II-III, RT + Atezo | S1933 | N | |||
Y | SWOG | S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac | S1701 | N | |||
Y | SWOG | S1900E KRAS G12C: Sotorasib (AMG 510) | S1900E | N | |||
Y | SWOG | S1934 Superior Sulcus NSCLC, Trimodality +/- Atezo | S1934 | N | |||
Y | ECOG-ACRIN | EA5191 NSCLC, Cabozantinib +/- Nivolumab vs Chemo | EA5191 | N | |||
LYMPH | Y | SWOG | S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | S1608 | N | Y | |
Y | ECOG-ACRIN | EA4181 MCL, Randomization BR/CR v BR/CR-A v BR-A | EA4181 | N | |||
MELAN | Y | SWOG | S2000 MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo | S2000 | N | ||
Y | ECOG-ACRIN | EA6192 Melan, Adv, Erly Discont of Antibdy Thrpy | EA6192 | N | |||
MMYEL | Y | SWOG | S2005 WM, Prev. Untreated, I/R +/- Venetoclax | S2005 | N | ||
Y | ECOG-ACRIN | EAA173 MYEL, SMM, Rd +/- Daratumumab | EAA173 | Y | |||
OTHER | Y | NRG | NRGBN001 HN, novel vs. std chemoradiation + chemo | NRG-BN001 | N | ||
Y | ECOG-ACRIN | EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp | EA3132 | N | |||
Y | ECOG-ACRIN | EAF151 Brain, GBM, Bev, Blood Volume | EAF151 | N | |||
Y | ECOG-ACRIN | EA3163 Nasal, T3 vs T4a, Surgery+RT +/- NeoAdj CT | EA3163 | N | |||
Y | ALLIANCE | A091802 cSCC, Advanced Avelumab +/- Cetuximab | A091802 | N | |||
Y | ALLIANCE | A071701 BRAIN, Met, Geno-guided trial | A071701 | N | |||
Y | ALLIANCE | A091902 Sarcoma, Paclit +/- Nivo and Nivo + Caboz | A091902 | N | |||
Y | ECOG-ACRIN | EA3191 HN, High Risk HNSCC, Adj +/- Pembro | EA3191 | N | |||
Y | NRG | NRGGY023 Ovar, Rando Durv Triplet TX vs Chemo | NRG-GY023 | N | |||
PREV | Y | ECOG-ACRIN | EA2185 Panc, Impact of Panc Cyst Surveillance | EA2185 | Y | ||
SXQOL | Y | ECOG-ACRIN | EAZ171 Breast, Stg I-III, TIPN Docetaxel/Paclitaxel | EAZ171 | Y | ||
PILOT | PREV | Y | SWOG | S1904 Breast, Decision making for chemoprevention | S1904 | Y | |
SXQOL | Y | ECOG-ACRIN | EAQ202 Improving AYA PROs in EA Trials | EAQ202 | Y | ||
II-III | BREAST | Y | NRG | NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA | NRG-BR002 | N | Y |
ERLYTX | Y | SWOG | S2012 Small Cell NEC, Stg IV, Combo Chemo +/- Atezo | S2012 | N | ||
GI | Y | NRG | NRGGI005 COLON,Stg IIA, ctDNA in Adjuvant Chemotherapy | NRG-GI005 | N | ||
Y | ECOG-ACRIN | EA2197 Gal, Rando Perioperative TX | EA2197 | N | |||
Y | ECOG-ACRIN | EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab | EA2174 | N | |||
GU | Y | NRG | NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel | NRG-GU002 | N | ||
Y | ECOG-ACRIN | EA8192 Blad, High Grade UTUC, Durv + Chemo | EA8192 | N | |||
LEUK | Y | ALLIANCE | A041701 AML, Age 60+, Conv Chemo +/- Uproleselan | A041701 | N | ||
LUNG | Y | SWOG | S1800D Non-Match: N-803 + Pembro vs SoC | S1800D | N | ||
Y | NRG | NRGCC003 SCLC, PCI or HA-PCI | NRG-CC003 | Y | |||
Y | NRG | NRGLU005 LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo | NRG-LU005 | Y | |||
Y | NRG | NRGLU002 LUNG, Limited Met NSCLC, MST vs LCT + MST | NRG-LU002 | Y | |||
LYMPH | Y | SWOG | S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | S1918 | Y | ||
Y | ALLIANCE | A051701 LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax | A051701 | N | Y | ||
MELAN | Y | ECOG-ACRIN | EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim | EA6141 | N | ||
OTHER | Y | NRG | NRGHN004 HN, Adv, RT+Durvalumab vs RT+Cetuximab | NRG-HN004 | Y | ||
Y | NRG | NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care | NRG-GY005 | Y | |||
Y | NRG | NRGHN005 HN, early stg P16-pos, randomize de-intensifi | NRG-HN005 | Y | |||
Y | ECOG-ACRIN | EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo | EA3161 | N | |||
Y | NRG | R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux | RTOG-1216 | Y | |||
Y | NRG | NRGHN001 Nasopharyngeal , Indiviual Tx EBV | NRG-HN001 | Y | |||
Y | NRG | NRGHN006 HN, Erly Stg, Biopsy vs Dissection | NRG-HN006 | Y | |||
Y | NRG | NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN | NRG-HN009 | Y | |||
Y | NRG | NRGBN007 Brain, New Dx, Ipi + Nivo vs Temozomide | NRG-BN007 | Y | |||
SXQOL | Y | ALLIANCE | A221805 Colorectal, Duloxetine for Oxaliplatin CIPN | A221805 | Y | ||
III | BREAST | Y | ALLIANCE | A011202 Breast, Nodal XRT +/- ALND | A011202 | N | |
Y | NRG | NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo | NRG-BR003 | N | |||
Y | NRG | NRGBR004 BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo | NRG-BR004 | Y | |||
Y | CCTG | MA39 BREAST, Node-Pos, Reg RT vs No Reg RT | CCTG MA.39 | Y | |||
Y | ALLIANCE | A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib | A011801 | Y | |||
Y | NRG | NRGBR007 Breast, Stg I, De-Escalation of Breast RT | NRG-BR007 | Y | |||
CCD | Y | SWOG | S1703 Met Breast, STM-monitoring v Usual Care | S1703 | Y | ||
Y | SWOG | S1912CD CREDIT, Fin Counseling to reduce Fin Hardship | S1912CD | Y | |||
Y | ALLIANCE | A191901 Brst, Text/Motivational Intervention ET Adher | A191901 | Y | |||
ERLYTX | Y | COG | AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | AGCT1531 | Y | ||
GI | Y | ALLIANCE | A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC | A021502 | Y | ||
Y | NRG | NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy | NRG-GI004 | Y | |||
Y | ALLIANCE | A021602 PANC, Adv PNET Blinded Cabozantinib v Placebo | A021602 | Y | |||
Y | ALLIANCE | A021703 COLON, Adv/Met, Chemo + Std v High dose V-D3 | A021703 | N | |||
Y | ALLIANCE | A021806 Pancreas, Perioperative vs Adjuvant Chemo | A021806 | Y | |||
Y | ECOG-ACRIN | EA2176 Anal, Met, Immune Check Pt Inhibition + Chemo | EA2176 | N | |||
GU | Y | SWOG | S1806 Blad, MIBC, ChemoRT +/- Atezolizumab | S1806 | Y | ||
Y | SWOG | S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum | S1802 | Y | |||
Y | SWOG | S1937 Blad, Mets, Eribulin +/- Gem vs SOC | S1937 | N | |||
Y | SWOG | S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only | S1931 | N | |||
Y | NRG | NRGGU005 PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT | NRG-GU005 | Y | |||
Y | ALLIANCE | A031704 RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo | A031704 | Y | |||
Y | ECOG-ACRIN | EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT | EA8134 | Y | |||
Y | ALLIANCE | A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) | A031102 | Y | |||
Y | NRG | NRGGU010 Pros, Parallel De-Intens & Intens Trials | NRG-GU010 | Y | |||
Y | ECOG-ACRIN | EA8191 Pros, Local vs Systemic Thrpy | EA8191 | N | |||
Y | ECOG-ACRIN | EA8183 Pros, Dbl Blind Andro Dep + Daro vs Placebo | EA8183 | Y | |||
Y | NRG | NRGGU009 Pros, PREDICT-RT | NRG-GU009 | Y | |||
Y | ALLIANCE | A031902 Pros, Adv, Enzalutamide + Rucaparib | A031902 | Y | |||
LEUK | Y | SWOG | S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O | S1925 | Y | ||
Y | ALLIANCE | A041702 CLL, Stg I-IV, IO with IM versus IVO | A041702 | N | |||
Y | ALLIANCE | A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo | A041501 | N | |||
Y | ECOG-ACRIN | EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab | EA9181 | N | |||
LUNG | Y | SWOG | S1827 SCLC, MRI Surveillance +/- PCI | S1827 | Y | ||
Y | SWOG | S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo | S1914 | Y | |||
Y | ECOG-ACRIN | EA5181 NSCLC, Unresect Stg 3, Chemo/RT+/-MED4736 | EA5181 | N | |||
Y | ECOG-ACRIN | E4512 ALCHEMIST2, ALK mut, Crizotinib | E4512 | N | |||
Y | ECOG-ACRIN | EA5163 NSCLC, Immunotherapy +/- 2nd line therapy | EA5163 | N | |||
Y | ALLIANCE | A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO | A081801 | Y | |||
Y | ECOG-ACRIN | EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 | EA5182 | N | |||
Y | NRG | R1308 Lung, Stg II/III, Photon vs Proton Chemo RT | RTOG-1308 | Y | |||
LYMPH | Y | SWOG | S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD | S1826 | Y | ||
Y | ALLIANCE | A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo | A051301 | N | |||
Y | ECOG-ACRIN | EA4151 Lymph, AHCT +/-Ritux, MRD Neg | EA4151 | N | |||
Y | COG | ANHL1931 PMBCL, Chemo-Immunotherapy +/- Nivo | ANHL1931 | N | |||
MELAN | Y | ECOG-ACRIN | EA6174 Merkel, Adjuvant Pembrolizumab vs Observation | EA6174 | N | ||
MMYEL | Y | SWOG | S1803 MM, Maintenance, Len vs Len/Dara | S1803 | N | ||
Y | ECOG-ACRIN | EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | EAA181 | Y | |||
OTHER | Y | ALLIANCE | N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC | N0577 | N | ||
Y | NRG | G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT | GOG-0263 | Y | |||
Y | NRG | NRGBN003 Mening, Grd II, Observation vs Irradiation | NRG-BN003 | Y | |||
Y | COG | AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo | AGCT1532 | Y | Y | ||
Y | NRG | R0724 Cervical, Chem+RT +/- Adj. Chemo | RTOG-0724 | Y | |||
Y | ALLIANCE | A071801 Brain, Mets, Post-Srg Single SRS vs Fract SRS | A071801 | Y | |||
Y | NRG | NRGGY018 Endo, Stg III-IVB/Recur, Pac/Carbo +/- Pembro | NRG-GY018 | Y | |||
Y | COG | ARST1431 Sarcoma, IR RMS, Randomized VAC/VI +/- TORI | ARST1431 | N | |||
Y | NRG | NRGGY020 Endo, Erly Stg, Rando RT +/- Pembro | NRG-GY020 | Y | |||
PREV | Y | SWOG | S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac | S0820 | Y | ||
Y | ECOG-ACRIN | EA1151 Prev, Tomosynthesis Mammographic Screening | EA1151 | N | |||
Y | ALLIANCE | A211102 Breast, Atypia via RPFNA, Metformin v Placebo | A211102 | Y | |||
SURV | Y | SWOG | S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol | S1501 | Y | ||
SXQOL | Y | SWOG | S1600 Bladder,Radical Cystectomy Outcomes Nutrition | S1600 | Y | ||
Y | SWOG | S1614 HBV in Ca Pts, anti-HBV therapy vs SOC | S1614 | Y | |||
Y | ALLIANCE | A221702 BREAST, SLN/ALND +/- ARM | A221702 | Y | |||
Y | ALLIANCE | A222004 Mult, Olanza vs Megestrol for Anorexia | A222004 | Y | |||
Y | SWOG | S2015 | S2015 |
Protocol Number |
Study | Accrual Goal |
Open Stat/Date |
Months Open |
Accrual as of 01Jan02 |
Current Accrual | Proj. Annual Accr. Rate |
EXPCLOSE | Proj. Study Duration (Years) |
---|---|---|---|---|---|---|---|---|---|
S0820 S0820 | PACES: ColrecStg0-3 Blind DFMO/Sulindac (PREV) | 491 | Y-03/01/13 | 112 | 339 | 339 | 26 | May-2028 | > 15 Yrs |
S1501 S1501 | Surv, Breast Stg IV, Card Tox w/ Carvedilol (SURV) | 817 | Y-09/15/17 | 57 | 273 | 273 | 26 | > 15 Yrs | > 15 Yrs |
S1600 S1600 | Bladder,Radical Cystectomy Outcomes Nutrition (SXQOL) | 200 | Y-02/21/19 | 40 | 140 | 140 | 36 | Feb-2024 | 5.0 |
S1614 S1614 | HBV in Ca Pts, anti-HBV therapy vs SOC (SXQOL) | 444 | Y-02/21/19 | 40 | 4 | 4 | 2 | > 15 Yrs | > 15 Yrs |
S1703 S1703 | Met Breast, STM-monitoring v Usual Care (CCD) | 1320 | Y-07/16/18 | 47 | 228 | 228 | 56 | > 15 Yrs | > 15 Yrs |
S1800D S1800D | Non-Match: N-803 + Pembro vs SoC (LUNG) | 478 | Y-02/15/22 | 4 | 25 | 25 | 64.024115 | Jul-2029 | 7.4 |
S1802 S1802 | Pros, Stg IV, SST +/- Surg/RT to Primary Tum (GU) | 1273 | Y-09/17/18 | 45 | 565 | 565 | 136 | Sep-2027 | 9.0 |
S1803 S1803 | MM, Maintenance, Len vs Len/Dara (MMYEL) | 1100 | Y-06/27/19 | 36 | 801 | 801 | 314 | Jun-2023 | 3.9 |
S1806 S1806 | Blad, MIBC, ChemoRT +/- Atezolizumab (GU) | 475 | Y-04/19/19 | 38 | 294 | 294 | 116 | Jan-2024 | 4.7 |
S1826 S1826 | HD, Adv, Age 12+, N+AVD vs BV+AVD (LYMPH) | 987 | Y-07/19/19 | 35 | 894 | 894 | 442 | Sep-2022 | 3.1 |
S1827 S1827 | SCLC, MRI Surveillance +/- PCI (LUNG) | 668 | Y-01/10/20 | 29 | 102 | 102 | 64 | May-2031 | 11.3 |
S1912CD S1912CD | CREDIT, Fin Counseling to reduce Fin Hardship (CCD) | 536 | Y-07/26/21 | 11 | 30 | 30 | 48 | Jan-2033 | 11.4 |
S1914 S1914 | NSCLC, High Risk Early Stg, SBRT +/- Atezo (LUNG) | 480 | Y-03/25/20 | 27 | 108 | 108 | 70 | Oct-2027 | 7.5 |
S1918 S1918 | DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP (LYMPH) | 422 | Y-03/19/21 | 15 | 35 | 35 | 32 | Aug-2034 | 13.4 |
S1925 S1925 | CLL/SLL, Newly Dx HR, Early vs Delayed V+O (LEUK) | 247 | Y-12/14/20 | 18 | 27 | 27 | 26 | Dec-2030 | 10.0 |
S1931 S1931 | RENAL, Stg IV, IO + Nephrectomy. vs IO Only (GU) | 332 | Y-11/16/20 | 19 | 33 | 33 | 32 | Nov-2031 | 11.0 |
S1937 S1937 | Blad, Mets, Eribulin +/- Gem vs SOC (GU) | 465 | Y-02/16/21 | 16 | 10 | 10 | 12 | > 15 Yrs | > 15 Yrs |
S2012 S2012 | Small Cell NEC, Stg IV, Combo Chemo +/- Atezo (ERLYTX) | 189 | Y-12/02/21 | 7 | 1 | 1 | 2 | > 15 Yrs | > 15 Yrs |
Accrual goals assume studies are not terminated early as a result of interim analysis. Studies may have accrual objectives specific to subsets of patients and are not reflected in this report. Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months. Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months. |